导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.02% | 2822/4773 |
| 近一周 | -2.29% | 1692/5462 |
| 近一月 | -4.38% | 2426/5421 |
| 近一季 | -7.92% | 2587/5209 |
| 近半年 | -3.05% | 2108/4920 |
| 近一年 | 0.63% | 2518/4366 |
| 近两年 | 47.89% | 1541/2954 |
| 近三年 | 29.39% | 1079/2253 |
| 成立以来 | 141.02% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.67% 3343/4961 |
12.76% 2124/5312 |
- - |
- - |
| 2025 | 20.90% 2070/4813 |
-1.01% 2530/3635 |
2.34% 1636/4076 |
19.06% 2193/4524 |
0.23% 2109/4813 |
| 2024 | 17.76% 657/3463 |
3.02% 635/2808 |
-1.13% 945/3014 |
17.79% 1119/3129 |
-1.85% 1860/3463 |
| 2023 | -9.14% 1114/2656 |
4.63% 900/2280 |
-4.00% 1008/2385 |
-2.96% 806/2515 |
-6.78% 1918/2655 |
| 2022 | -19.78% 894/2207 |
-14.44% 945/1919 |
7.25% 502/2016 |
-14.27% 1056/2113 |
1.97% 1072/2208 |
| 2021 | -3.03% 884/1822 |
-3.10% 760/1255 |
4.48% 881/1330 |
-5.82% 865/1466 |
1.69% 835/1822 |
| 2020 | 30.56% 519/1250 |
-9.88% 728/1028 |
14.10% 570/1067 |
11.57% 435/1164 |
13.81% 329/1184 |
| 2019 | 38.71% 300/1092 |
28.20% 324/754 |
0.05% 203/804 |
0.75% 472/850 |
7.34% 448/918 |
| 2018 | -23.55% 289/834 |
- - |
- - |
- - |
-12.27% 431/691 |
| 2017 | 23.77% 130/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.14% 258/605 |
- - |
- - |
- - |
- - |
| 2015 | 6.42% 193/575 |
- - |
- - |
- - |
- - |
| 2014 | 54.38% 57/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达沪深300发起式ETF VS. 长安沪深300非周期A(740101) |